Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.59 USD
Change Today -0.005 / -0.85%
Volume 9.8K
As of 8:10 PM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).

arno therapeutics inc (ARNI) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/7/14 - $1.78
52 Week Low
12/16/14 - $0.43
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ARNO THERAPEUTICS INC (ARNI)

Related News

No related news articles were found.

arno therapeutics inc (ARNI) Related Businessweek News

No Related Businessweek News Found

arno therapeutics inc (ARNI) Details

Arno Therapeutics, Inc. focuses on developing products for the treatment of cancer and other life threatening diseases. Its product development pipeline includes Onapristone, a type 1 anti-progestin hormone blocker, which is in Phase I/II clinical trials for the treatment of breast, endometrial, and others solid tumors in post-menopausal women; and advanced castration-resistant prostate cancer in men. The company’s products in development also comprise AR-42, an orally available spectrum inhibitor of histone and non-histone deacetylation proteins that is in Phase I investigator-initiated clinical study for the treatment of hematological malignancies and solid tumors In addition, it is developing AR-12, an orally available cancer treatment, which has completed Phase I clinical study for the treatment of solid tumors and hematological malignancies; and is in Pre-clinical studies for the treatment of various anti-microbial targets. The company has a development and commercialization agreement with Leica Biosystems Newcastle Ltd. and a license agreement with Invivis Pharmaceuticals, Inc. to develop and commercialize Onapristone; patent license agreement with the regents of the University of Minnesota; license agreements with The Ohio State University Research Foundation to commercialize patent applications, know-how, and improvements relating to AR-12 and AR-42; and research and development agreement with US Army Medical Research Institute of Infectious Diseases to test antiviral activity of AR-12. Arno Therapeutics, Inc. is based in Flemington, New Jersey.

7 Employees
Last Reported Date: 03/31/15

arno therapeutics inc (ARNI) Top Compensated Officers

Chief Executive Officer, Chief Medical Office...
Total Annual Compensation: $615.3K
Chief Financial Officer, Chief Operating Offi...
Total Annual Compensation: $311.8K
Chief Development Officer
Total Annual Compensation: $306.6K
Compensation as of Fiscal Year 2014.

arno therapeutics inc (ARNI) Key Developments

Arno Therapeutics, Inc. Announces Cooperative Research and Development Agreement with US Army Medical Research Institute of Infectious Diseases to Test Antiviral Activity of AR-12

Arno Therapeutics, Inc. announced it has entered into a Cooperative Research and Development Agreement (CRADA) Material Transfer Agreement with the US Army Medical Research Institute of Infectious Diseases (USAMRIID) to evaluate the anti-viral activity of AR-12 and various analogues against Ebola and other viruses of biodefense interest. AR-12 is an orally-available small molecule. Data reported previously demonstrate that the AR-12 mechanism of action may include induction of host cell autophagy and inhibition of fungal acetyl coenzyme A synthetase. The precise antiviral mechanism of action of AR-12 continues to be evaluated but an established body of evidence demonstrates that AR-12 is an inducer of host effector cell autophagy. AR-12 is known to inhibit, or down regulate, GRP78 (also known as BiP, HSPA5) the master regulator of the unfolded protein response. The down regulation of GRP78 results in the up-regulation of PERK which induces the formation of autophagosomes and, subsequently, host cell autophagy. AR-12 also down regulates the chaperone proteins HSP70 and HSP90. Previously, AR-12 has completed Phase 1 clinical trials in patients with cancer. Additional pre-clinical research indicates that AR-12 may have potential as an antimicrobial agent in various infectious diseases. AR-12 has been granted two orphan drug designations in Europe for the treatment of cryptococcosis and tularaemia. In addition, Arno also has the rights to a broad portfolio of compounds in the "AR-12 series" which have been demonstrated to have broad spectrum antimicrobial activity.

Arno Therapeutics, Inc. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2015

Arno Therapeutics, Inc. reported unaudited earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported loss from operations of $3.863 million against $6.164 million a year ago. Net loss was $3.389 million or $0.17 per basic and diluted share compared to $0.446 million or $0.02 per basic and diluted share a year ago. Adjusted non-GAAP net loss was $2.865 million or $0.14 per share against $4.988 million or $0.24 per share a year ago.

Arno Therapeutics, Inc. Announces Promising Data Supporting the Ongoing Clinical Development Program for Lead Compound Onapristone

Arno Therapeutics, Inc. announced promising data supporting the ongoing clinical development program for lead compound onapristone to be presented at the upcoming 2015 American Society of Clinical Oncology Annual Meeting, being held May 29-June 2 in Chicago, IL. Results from Phase 1 study in women with progesterone (PR) positive tumors have been immensely informative and critical to the advancement of onapristone clinical development program. In addition to demonstrating clinical benefit in a group of heavily pre-treated patients, the study demonstrated that Arno's highly purified onapristone extended-release formulation has a very manageable safety profile, providing the recommended dose for the Phase 2 study currently underway. Additionally, results from the first portion of Phase 1/2 study in men with advanced castration-resistant prostate cancer (CRPC) confirm the very acceptable safety profile of onapristone. An ongoing Phase 2 clinical trial is evaluating the safety and efficacy of onapristone in post-menopausal women with recurrent or metastatic uterine endometrioid cancer that is APR positive. In addition, the trial is evaluating the companion diagnostic, which is being developed to detect APR in patients with endometrioid cancer to identify those patients more likely to respond to onapristone. The ongoing Phase 2 study is actively recruiting post-menopausal women with recurrent or metastatic uterine endometrioid cancer that is APR positive. At study entry, patients' APR status is determined by immunohistochemistry (IHC) on biopsy with slides stained using a technically-validated procedure and interpreted by trained pathologists. Patients are treated with the recommended Phase 2 dose (RP2D) of 50mg extended-release onapristone twice daily (BID) as determined by the Phase I portion of the trial until progressive disease or intolerability. The primary endpoint is objective response rate by RECIST 1.1, with secondary endpoints including relationship between extent of APR expression and onapristone activity, safety and tolerability, duration of response, progression-free survival (PFS) and overall survival (OS). The Simon 2-stage design of the Phase 2 study includes 10 patients in the first stage. If two or more patients respond, the study will recruit an additional 19 patients (stage 2) to confirm anti-tumor activity.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ARNI:US $0.59 USD -0.005

ARNI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ARNI.
View Industry Companies

Industry Analysis


Industry Average

Valuation ARNI Industry Range
Price/Earnings 3.0x
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow 2.5x
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ARNO THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at